CoVaRR-Net Funded Research Results

CoVaRR-Net Funded Research Results2022-08-09T12:55:08-04:00

Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants

September 26, 2022|Funded Research Results, Pillar 3|

mRNA-based vaccines are currently the most widely used vaccines for COVID-19. Challenges surrounding these novel vaccines such as mRNA-based vaccine hesitancy, production costs and demand, delivery, and unknown longevity of protection have highlighted the need for alternative vaccine strategies.

The Hunan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic

July 26, 2022|Funded Research Results, Pillar 2|

A recent study addressing the origins of the COVID-19 pandemic has been published in the journal Science by a team of 18 scientists led by Michael Worobey and including CoVaRR-Net Pillar 2 lead Angela Rasmussen, virologist at the University of Saskatchewan’s Vaccine and Infectious Disease Organization, and an adjunct professor of biochemistry, microbiology, and immunology at the University of Saskatchewan.

COVID-19 Vaccination and Public Health Countermeasures on Variants of Concern in Canada: Evidence From a Spatial Hierarchical Cluster Analysis

June 9, 2022|Funded Research Results, Pillar 8|

With variants of concern (VOCs) continuing to emerge and pose health challenges in Canada, scientists, including Dr. Nazeem Muhajarine from the University of Saskatchewan and CoVaRR-Net Pillar 8 Public Health, Health Systems and Social Policy Impacts Co-Lead, are strategizing on how to control their effects on the Canadian population.

Go to Top